Objectives To investigate the effect of false positive breast screening examination results on subsequent attendance in the UK National Health Service Breast Screening Programme. Methods 253,017 previously screened women who were invited for rescreening were studied. Attendance rates of women who had received a normal result at the last (index) screen were compared with those of women who had received a false positive result. The effects of age, type of index screening examination ( prevalent or incident) and tissue sampling at assessment were investigated.
INTRODUCTION

M
ammographic screening for breast cancer has been the subject of intense debate in recent years, particularly regarding the balance between the benefit in terms of mortality reduction and potential harms such as overdiagnosis (the diagnosis and treatment of cancers which are otherwise unlikely to harm the patient). 1, 2 Because of the relatively low specificity of mammography, especially in women being screened for the first time (most of whom do not have prior mammograms for comparison), several women with mammographic abnormalities are recalled for further investigation in order to diagnose one breast cancer. Previous studies have suggested that this leads to long term anxiety in the women who have false positive results from screening, who may therefore be less likely to attend subsequent screening invitations. 3 Only three studies of reattendance of women undergoing routine breast screening in the UK National Health Service (NHS) breast screening programme have previously been published, and these gave conflicting findings. O'Sullivan et al 4 suggested that false positive screening does not reduce subsequent attendance, but Brett et al 5 and McCann et al 6 claimed that it does. These studies were published over ten years ago, during which time the breast screening programme has changed significantly, with increasing use being made of percutaneous needle biopsy and a concomitant reduction in the use of surgery for diagnostic purposes. Although a number of studies from other countries have been published in the meantime 7 -18 , differences in the characteristics of the populations screened and the differing organization of screening programmes elsewhere means that the findings of these studies may not be applicable to the UK.
This study was designed to investigate the effect of false positive breast screening on attendance at the next routine screening invitation in the UK National Health Service Breast Screening Programme (NHSBSP). In particular, we were interested in determining whether factors such as type of screening examination ( prevalent or incident), age and the use of needle or open surgical biopsy at assessment have an effect.
METHODS
This retrospective cohort study was funded by NHS North West. Confirmation that ethical approval was not required was obtained from the National Research Ethics Service. Women invited for screening are informed that screening records are regularly reviewed and audits performed. 19 Women in the United Kingdom aged between 50 and 70 are sent an appointment for breast screening every three years. This is a continuous cycle, with women grouped into batches according to the location and identity of their general practitioner. This allows local screening programmes that use mobile mammography facilities to offer screening close to home for most women. A small proportion of women screened in the study period in the five programmes were placed on early recall following initial assessment (see Table 1 ), whereby they underwent repeat imaging in the assessment clinic after an interval (usually one year). Women who had been placed on early recall and had a normal or benign final outcome were included in the study although their repeat assessment attendances were not included.
Five English breast screening services were included in the study: Bolton, Bury and Rochdale; Cambridge and Huntingdon; Gloucestershire; Liverpool; and North Lancashire and South Cumbria. The study size was comparable with similar studies performed in other countries 7, 10, 12, 14 , although significantly smaller than some very large studies. 15, 17, 18 The screening services included in the study represent a balanced cross-section of the population in different parts of the country, and include ethnic minority communities and rural and inner city populations. Indices of multiple deprivation (IMDs) were obtained for those Primary Care Trusts (PCTs -the local commissioners of health care during the study period) whose main screening provider was one of the five programmes included in the study. IMD is a measure of the level of deprivation of local communities, taking into account factors such as income, employment, health deprivation and education. A low figure refers to the least deprived. The median 2007 IMD for the 12 PCTs covered by the study screening programmes was 23.3 (range 11.5 to 47.0) which is very similar to the median for all 152 English PCTs of 23.6 (range 8.1 to 48.3). 21 Screening invitation, attendance, and result data collation for breast screening in England are managed through the computerized National Breast Screening System (NBSS). A Crystal report (a piece of software used to extract selected data from the database) was commissioned to identify women who had attended screening after a first offered appointment within the study period of 1 April 2005 to 31 March 2008. This period covers a full three year screening cycle, thus minimizing any skew in reattendance behaviour that might occur if only part of the screening cycle was studied (women are invited for screening according to their GP practice and therefore the characteristics of the population screened vary depending on the part of the cycle under consideration). The first offered appointment is a key date used by NBSS, and is the date of the first appointment for screening mammography offered to the woman in the current screening round. Approximately 30% of women fail to attend, and a substantial proportion of those who do attend only do so after changing their appointment to a more convenient one. As routine screening is only offered to women between the ages of 50 and 70, only women who were aged between 50 and 67 at the first offered appointment for the last screen and had been sent a further appointment between 1 and 3.5 years later were included in the study.
Women who had been diagnosed with cancer at screening following a first offered appointment during the study period were excluded. The Crystal report was designed to extract the following data: date of screening examination; type of screening examination, ie. the woman's first ( prevalent) or a subsequent (incident); the woman's age at screening; the outcome of the screening examination (normal or false positive); and the assessment procedures performed for those with false positive screening examination results (needle sampling and/or open biopsy). Needle sampling included fine needle aspiration cytology and/or needle core biopsy. For those women who were not screened, the reasons for screening not being performed were extracted.
The report was run in each of the five screening centres and the results were collated. Women were classified as attenders if they underwent screening or if they attended the screening appointment but for any reason did not undergo mammography. Women were classified as non-attenders if they were either coded on NBSS as non-attenders or nonresponders or if they had opted out. Women who had died, moved away or had recently undergone mammography outside the NHS breast screening programme (e.g. diagnostic or privately provided screening mammography) and/or were 'under care' (mostly women already on surveillance following treatment for breast cancer) were excluded before analysis. Statistical analysis was carried out using Stata version IC 10 and StatsDirect version 2.7.7. Percentages and their 95% confidence intervals (CIs) of reattendance at the subsequent screening invitation were calculated between those women who had normal and false positive screening examinations. These results were further stratified by whether or not the initial screening examination had been prevalent or incident. Logistic regression was carried out within the subgroups of prevalent and incident screened women to assess the association of age, needle sampling and open biopsy with reattendance. These regressions were clustered on the five centres. The odds ratios (ORs) and their 95% CIs were used to assess their statistical significance. ORs per centre were presented within Forest plots with I 2 statistics to assess heterogeneity.
RESULTS
The Crystal reports yielded a total of 264,274 women from the five screening programmes. This number represents all the women who underwent screening examinations in the five centres in the study period, minus those who were diagnosed with breast cancer. Of these, 11,257 women were excluded for the reasons stated above (death, moving away, etc.), leaving 253,017 for analysis. For clarity, the screening examinations performed during the 2005-8 round are referred to as the index screening examinations. Table 1 shows the attendance, assessment and early recall rates for the five screening programmes during the study period of 2005-8. Table 2 shows the number of women included from each of the five programmes and the number of women who had false positive screening results, including the number of women who underwent needle sampling and/or open surgical biopsy. The median age of the women undergoing prevalent index screening examinations was 51, with a range of 47 to 66 and an interquartile range of 50 to 52 (data not shown). The median age of the women undergoing incident index screening examinations was 59, with a range of 49 to 66 and an interquartile range of 56 to 62. The median ages of women undergoing prevalent and incident index screening examinations in each of the centres were 51 and 59-60 respectively.
The numbers of women who reattended for screening after normal and false positive index screening examination results are stratified by prevalent and incident index screening examinations and are shown in Table 3 . This demonstrates that the proportion of women who reattended after false positive prevalent index screening examinations is slightly but significantly higher than the proportion of women reattending after normal prevalent index screening examinations (87.7% vs. 86.0%, difference ¼ 1.61%, 95% CI ¼ 0.54% to 2.62%). There is a slight non-statistically significant reduction in reattendance of women who had a false positive incident index screening examination result compared with women who had a normal incident index screening examination result (92.0% vs. 92.4%, difference ¼ 20.40%, 95% CI ¼ 21.18% to 0.31%). Reattendance was higher following incident compared with prevalent index screening examinations (92.4% vs. 86.2%). This higher percentage still held after stratifying by false positive and normal index screening examination result status.
The effect of needle sampling at assessment, open surgical biopsy and age across the five centres is shown in Tables 4  and 5 .
Needle sampling
Women who underwent needle sampling (without open biopsy) as a result of a prevalent index screening examination show no significant difference in reattendance rate compared with women whose index screening examinations were normal ( p ¼ 0.492). However, needle sampling after incident screening examinations results in a 12% reduction in the odds of reattending ( p , 0.001).
Open surgical biopsy
Women who underwent open surgical biopsy following a prevalent screening examination show a non-significant reduction in subsequent attendance compared with women who had a normal screening examination. Women who underwent open biopsy after an incident index screening examination showed a 60% reduction in the odds of reattendance ( p , 0.001). The number of women in these groups, however, is small, and the odds ratio has wide confidence intervals.
No tissue sampling
Women who were recalled for assessment but did not undergo tissue sampling after a prevalent index screening examination were 20% more likely to reattend than women whose prevalent index screening examination was normal ( p , 0.001). The odds of reattendance following assessment after an incident index screening examination were identical to those of women whose incident index screening examination was normal.
Age
Increasing age results in a statistically significant reduction in the odds of reattendance. For each year's increase in a woman's age at the prevalent index screening examination there is a reduction in the odds of reattendance of 11%. Following incident index screening examinations the corresponding reduction is 1%.
Differences between centres
The ORs of reattendance by false positive screen type and prevalent/incident index screening examination, per centre, are presented in Figures 1 and 2 . There is little evidence of heterogeneity between centres for those who had a false positive result and either no tissue sampling or needle sampling only. However there was heterogeneity for those who underwent open biopsy, following both prevalent and incident screening examinations. For prevalent screening examinations, the results of two centres indicate that women were more likely to attend after a false positive index screen result with open biopsy with very similar odds ratios (2.9 to 3.1). The other three centres indicate that women with this result were less likely to reattend (ORs: 0.3 to 0.6). For incident screening examinations the results were similar, except that four centres indicated that women with false-positive results with open biopsy were less likely to re-attend (ORs: 0.2 to 0.5).
The ORs for all screening types and centres shown in Figures 1 and 2 (which are not age adjusted) differed by no more than 7% compared with the ORs adjusted for age in Tables 4 and 5 . Pooled ORs (which account for difference in variation and sample size between centres) were similar to the overall ORs given in Tables 4 and 5 (less than 5% change for all ORs).
DISCUSSION
This multicentre study addresses a number of the themes included in the objectives of the NHS Breast Screening Programme
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, including acceptability of the service to users, minimization of adverse effects and programme evaluation and feedback to the public. The findings indicate that, overall, women who have received false positive screening results in the UK do not have a reduced rate of attendance for screening at the next invitation. Indeed, those who had a false positive first screening examination result are significantly more likely to reattend than those who had a normal first screening examination result (due mostly to the behaviour of those who had no tissue sampling), despite the fact that the overall reattendance of women who had been screened only once was six percentage points lower than that of women who had been screened more than once. Needle sampling results in a significantly reduced rate of reattendance when it takes place after incident but not prevalent screening examinations.
The effects of open biopsy are not consistent between the five centres studied, but overall open biopsy resulted in a reduction in reattendance when it took place after incident screening examinations. It should be noted that false positive incident screening examination results comprise nearly 55% of the total (Table 3) .
The findings from a number of studies of reattendance after false positive breast screening results have been inconsistent. A systematic review in 2007 (Brewer et al 11 ) of the long term effects of false positive screening mammography included a meta-analysis of 12 papers on reattendance 4 -10,23 -27 , and concluded that American women who have received false positive breast screening results are more likely to attend a subsequent screening invitation than women who had received a normal result, whereas there was no significant effect for European women, and Canadian women are less likely to attend subsequently. The meta-analysis was updated in 2011 16 with the addition of another two European studies 12, 13 but with no change in the conclusion. Two further European studies 15, 17 and a recently published study from Australia 18 found that false positive screening reduced subsequent attendance whereas a study of the Irish BreastCheck programme 14 found a small but significant increase in reattendance following false positive mammography.
Three British studies examining reattendance in the UK NHS Breast Screening Programme have previously been published and all were included in Brewer's review. O'Sullivan et al 4 reported a single centre study which showed no significant difference in reattendance rate between women invited for screening following normal and false positive screening examinations respectively. However, Brett and Austoker, in study of 505 women 5 , found a moderate reduction in reattendance in those who had previously had a false positive screening examination. McCann 6 studied 140,387 women aged 50 to 62 who had undergone a first (prevalent) screening examination between 1989 and 1995, and found a reduction in reattendance for those who had received a normal result (this included women who had undergone needle sampling) (OR ¼ 0.84) and in those who had undergone open benign biopsy (OR ¼ 0.65). A fourth British study 28 reported the reattendance of women in their forties who were undergoing annual mammography in the UK Age Trial, and found no significant overall effect of false positive screening examinations on reattendance. These inconsistencies between published studies are probably due to a number of factors, such as the age range of women invited, the type of screening (organized programme or ad hoc), differences in screening interval, ease of access to the screening mammography and assessment facilities, the information provided to the woman before and during the screening process, the communication skills of the individuals working in the screening programmes, and cultural differences between screened populations. In particular it should be noted that the three published studies of reattendance of women undergoing routine screening in the UK NHSBSP are not typical of modern UK screening practice. One 4 was a small study conducted in a single screening programme where reattendance was measured following an index screen in 1997, over seven years before the start of our study period. Brett and Austoker 5 examined the reattendance of a small group of women who had agreed in 1995-1996 to participate in a questionnaire study of the psychological effects of breast screening. The third 6 was a study of women invited for their first screening examination at the start of the screening programme in East Anglia between 10 and 17 years before our study group underwent their index screening examinations. It contains a large proportion of women who underwent their first screening examination at a significantly higher age than the women in our study. Women in the UK Age Trial 28 were all less than 50 years old, and may have been more motivated than other women to reattend by virtue of their voluntary trial participation.
There is wider agreement amongst most of the published studies on a number of other factors which negatively affect screening reattendance, including increasing age and the experience of invasive tests at assessment, particularly open surgical biopsy. In a small proportion of cases this may be because women are subsequently screened outside the screening programme as a result of biopsy findings of 'high risk' lesions such as atypical ductal or lobular hyperplasia or lobular carcinoma in situ, but these cases are unlikely to account for the majority of this effect. In this study a reduced attendance after tissue sampling was only seen in those who had false positive incident index screening examination results, although the number of women who underwent open biopsy after prevalent index screening examinations is small. The increasing use of percutaneous vacuum-assisted biopsy should reduce the number of women undergoing open diagnostic biopsy and thus reduce this negative effect upon reattendance.
Although only a small proportion of the 93 breast screening centres in the UK were studied, the varied nature of the populations included in this study and the similarity of the deprivation indices of the study population to the national figures suggest that similar patterns of reattendance would be seen in other UK units. Women who underwent open biopsy following false positive screening examination results account for only 0.02% of the women in the study, and the variation in their reattendance (as seen between centres in this study) is unlikely to contribute greatly to overall variation in reattendance between other UK centres. Some variation in assessment practice between the five centres is also evident from the differences in the short term recall rates shown in Table 1 . The relatively high rate seen in the Gloucestershire programme during 2005-8 has since reduced.
The reason for increased attendance found in this study following false positive prevalent index screening examination results but not after false positive incident index screening examination results is unclear. False positive screening examination results certainly lead to short-term anxiety in many women, some of whom experience longer term anxiety after receipt of the normal screening result. 3, 29, 30 This has been used as an argument both for increased 31 and decreased 5 subsequent attendance, although the reduction in attendance that occurs following tissue sampling suggests that screening-induced anxiety is probably not responsible for the overall increased subsequent attendance. Nonetheless the interaction of women's screening experiences and false-positive-induced anxiety is unclear. 32 The influence of screening examination type ( prevalent or incident) has not previously been well studied. A lower reattendance rate following false positive prevalent index screening examination results compared with false positive incident index screening examination results (as seen in this study) was also found in the Irish study.
14 It is noteworthy that in our study a similar effect was seen also in the women who had normal index screening examination results, which suggests that a proportion of women who previously attended are put off doing so again by the experience of their first screen. In the majority of cases this is likely to be because of pain or discomfort experienced during mammography. 33 This deserves further study, as overcoming barriers to reattendance at this point may significantly increase the numbers of women taking up screening invitations.
The absence of a reduction in overall reattendance after false positive breast screening examination results suggests that the majority of women who go through the assessment process retain confidence in breast screening. However, needle sampling and especially open biopsy should be used judiciously in the assessment of screen-detected abnormalities in view of the reduction in reattendance that is seen when these procedures are performed after false positive incident screening examinations. 
